BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Merck KGaA (MKGAF.PK) Drug Fails in Late-Stage Brain Cancer Trial


2/25/2013 8:33:54 AM

Merck KGaA’s (MRK) experimental tumor- fighting drug cilengitide failed to help patients with a form of brain cancer in a late-stage clinical trial, adding to recent drug-development setbacks for the company. The medicine didn’t significantly increase survival in patients with newly diagnosed glioblastoma when added to standard chemotherapy, the Darmstadt, Germany-based drugmaker said in a statement today. Merck shares fell as much as 2.8 percent, the biggest intraday slide in two months, and were down 0.6 percent at 105 euros at 9:45 a.m. in Frankfurt. The setback comes after the family-controlled chemicals and pharmaceuticals company said in December that a therapy known as L-BLP25 failed to improve survival significantly in lung-cancer patients. “The results of Centric are disappointing, especially for people who are fighting this devastating and difficult-to-treat cancer,” said Annalisa Jenkins, the head of global drug development and medical for Merck’s prescription medicines division. “We remain committed to advancing our pipeline and developing new treatment options in oncology for patients with high medical need.”

Read at BusinessWeek
Read at Fox News
Read at RTT News
Read at News Release


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->